Company Overview and News
Synaptics (SYNA - Free Report) earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average positive earnings surprise of 4.7%. With expected long-term earnings per share growth rate of 10% and a market cap of $1.63 billion, it seems to be a stock that investors should keep in their portfolio for now. Let’s take a look at the factors that have been influencing the company’s performance.
SYNA MSFT AMD UTX BIDU EOG
Yesterday, Micron Technology (MU) reported a very impressive EPS of $3.53 for the most recent quarter, but projected an EPS of only $2.95 (plus or minus $0.07) for the current quarter. At first glance, a sequential EPS decline of 16% seems rather catastrophic, and suggests that perhaps the ongoing boom in the memory industry is in for a drastic reversal over the next several quarters. It may initially seem as if all the warnings about storm clouds, cyclicality, and weakening demand are coming true.
2018-09-21 247wallst - 1
Stocks were indicated marginally higher on Friday, but this as after the Dow Jones industrials and S&P 500 hit all-time high closes on Thursday. International markets were also higher on Friday, but many international and emerging markets are still very far away from their all-time highs. As many investors have seen lower upside from buying on market pullbacks than in prior years, they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
WFCNP CPRT UAA FSCT DRI AMD ETN NVAX AYI.WI AAI EDIT ASUV AA WFC AYI NBEV DO ACAD UA ABRW T TRI HLIT
The First Trust Multi Cap Growth AlphaDEX Fund (FAD - Free Report) made its debut on 05/08/2007, and is a smart beta exchange traded fund that provides broad exposure to the Total Market (U.S.) ETFs category of the market.
SQ AMD ILMN FPX
Shares of Advanced Micro Devices Inc. AMD, -0.10% are up 0.8% in premarket trading Friday after Jefferies analyst Mark Lipacis raised his price target on the stock to $36 from $30. He maintained a buy rating. Lipacis cited a report from Fubon Research that said Intel Corp. INTC, +2.28% would undersupply the market through the middle of next year. The report "leaves us with higher conviction that AMD will report improving revenue, pricing and margins near term, and that is positioned to take share in the high-end PC MPU and server market long term," Lipacis wrote.
2018-09-20 investorplace - 2
What a difference a month makes. Not that long ago, Facebook (NASDAQ:FB) was riding high again. After the Cambridge Analytica scandal knocked Facebook stock down from $190 to $150, the shares quickly bounced back. Following reassuring testimony from Mark Zuckerburg in front of Congress and a blowout earnings report, Facebook stock quickly shot up to new, all-time highs.
FB AMZN GOOGL TWTR TSLA AMD NFLX GOOG SNAP
2018-09-20 investorplace - 1
Advanced Micro Devices (NASDAQ:AMD) is a momentum stock for the ages. For its qualifications, look no further than the meteoric rise of the past five months. Since carving out a low of $9.04 on April 4, AMD stock has risen an astronomic 254%. While still a far cry from the insanity of Tilray (NASDAQ:TLRY) stock’s rocket ship ride, Advanced Micro Devices deserves your attention.
It wasn’t easy or pretty, but the market managed to tack on a bit of a gain on Wednesday. Though yesterday’s 0.13% advance from the S&P 500 was nowhere near Tuesday’s rally, it’s still another step forward. The index’s close of 2,907.95 was the second-best close ever.
CRON AMD TLRY KLAC IVZ WY
BENGALURU (Sept 20): The Dow Industrial Average on Thursday became the last of the benchmark indexes to regain record territory, boosted by gains in industrial companies on continued relief that fresh US and China tariffs were less damaging than feared.
UA GEC GE UAA GNE AMD
(Reuters) - The Dow Industrial Average on Thursday became the last of the benchmark indexes to regain record territory, boosted by gains in industrial companies on continued relief that fresh U.S. and China tariffs were less damaging than feared.
UA GEC GE UAA GNE AMD
Stifel is getting more bullish on AMD shares because of the chipmaker's rising profit margins and market share gains.
U.S. stock index futures pointed to a higher opening on Thursday, extending a bounce since the latest blows in the U.S.-China trade spat this week on the back of a recovery for technology stocks.
UA GEC GE UAA DRI GNE AMD RHT
(Reuters) - U.S. stock index futures pointed to a higher opening on Thursday, extending a bounce since the latest blows in the U.S.-China trade spat this week on the back of a recovery for technology stocks.
UA GEC GE UAA DRI GNE AMD RHT
2017-09-28 - Asif
We are a global semiconductor company with facilities around the world. Within the global semiconductor industry, we offer primarily: x86 microprocessors, as standalone devices or as incorporated as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs) and professional graphics processors; and server and embedded processors, semi-custom System-on-Chip (SoC) products and technology for game consoles. We also license portions of our intellectual property portfolio. In this section, we will describe the general financial condition and the results of operations of Advanced Micro Devices, Inc. and its wholly-owned subsidiaries (collectively, “us,” “our” or “AMD”), including a discussion of our results of operations for the quarter and six months ended July 1, 2017 compared to the quarter and six months ended June 25, 2016 , an analysis of changes in our financial condition and a discussion of our contractual obligations. We believe our fin...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to AMD / Advanced Micro Devices, Inc. on message board site Silicon Investor.
as of ET